142 related articles for article (PubMed ID: 6230139)
1. Aging of natural and acquired immunity of mice. II. Decreased T cell responses to syngeneic tumor cells and parental-strain spleen cells.
Fitzgerald PA; Bennett M
Cancer Invest; 1983; 1(2):139-49. PubMed ID: 6230139
[TBL] [Abstract][Full Text] [Related]
2. Non-H-2-linked genetic regulation of cytotoxic responses to hapten-modified syngeneic cells. I. Non-H-2-linked Ir gene defect expressed on T cells is not predetermined at the stage of bone marrow cells.
Ogata M; Shimizu J; Tsuchida T; Takai Y; Fujiwara H; Hamaoka T
J Immunol; 1986 Feb; 136(4):1178-85. PubMed ID: 2935573
[TBL] [Abstract][Full Text] [Related]
3. The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.
Nagarkatti M; Kaplan AM
J Immunol; 1985 Aug; 135(2):1510-7. PubMed ID: 3159794
[TBL] [Abstract][Full Text] [Related]
4. T-cell cytotoxicity and aging: differing causes of reduced response in individual mice.
Zharhary D; Segev Y; Gershon HE
Mech Ageing Dev; 1984; 25(1-2):129-40. PubMed ID: 6233460
[TBL] [Abstract][Full Text] [Related]
5. Hybrid resistance to EL-4 lymphoma cells. II. Association between loss of hybrid resistance and detection of suppressor cells after treatment of mice with 89Sr.
Leuvano E; Kumar V; Bennett M
Scand J Immunol; 1981; 13(6):563-71. PubMed ID: 6458878
[TBL] [Abstract][Full Text] [Related]
6. T-cell responses induced by the parenteral injection of antigen-modified syngeneic cells. II. Mechanisms, specificity, and cellular analysis of 2,4,6-trinitrophenol (TNP)-specific cytolytic response priming by intravenous versus subcutaneous injection with TNP-modified syngeneic cells.
Miller SD; Butler LD; Cleveland RP; Moorhead JW; Claman HN; Chiller JC
Cell Immunol; 1983 Dec; 82(2):378-93. PubMed ID: 6197193
[TBL] [Abstract][Full Text] [Related]
7. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
8. Correlations of in vivo growth of CTL-susceptible and -resistant variant tumor cell lines in CTL-responder AKR.H-2b:Fv-1b and -nonresponder AKR.H-2b mice.
Azuma H; Wegmann KW; Green WR
Cell Immunol; 1988 Oct; 116(1):123-34. PubMed ID: 3262427
[TBL] [Abstract][Full Text] [Related]
9. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
[TBL] [Abstract][Full Text] [Related]
10. Generation of specific antitumor cytotoxic T-lymphocytes in monoculture can be inhibited by T-suppressors from tumor-bearing mice.
Lupatov AYu ; Brondz BD
Cancer Biother; 1994; 9(2):123-9. PubMed ID: 7812361
[TBL] [Abstract][Full Text] [Related]
11. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
Carayanniotis G; Halloran PF
Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
[TBL] [Abstract][Full Text] [Related]
12. In vivo regulation of the cytolytic T cell response to hapten-altered self: suppressor T cells induced in the regional lymph nodes by exposure to syngeneic spleen cells.
Wong HL; Battisto JR
Eur J Immunol; 1984 Jul; 14(7):629-33. PubMed ID: 6235115
[TBL] [Abstract][Full Text] [Related]
13. Aging of natural and acquired immunity of mice. I. Decreased natural killer cell function and hybrid resistance.
Fitzgerald PA; Bennett M
Cancer Invest; 1983; 1(1):15-24. PubMed ID: 6365265
[TBL] [Abstract][Full Text] [Related]
14. Hybrid resistance to EL-4 lymphoma cells. I. Characterization of natural killer cells that lyse EL-4 cells and their distinction from marrow-dependent natural killer cells.
Kumar V; Luevano E; Bennett M
J Exp Med; 1979 Sep; 150(3):531-47. PubMed ID: 383877
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
Bear HD
Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
[TBL] [Abstract][Full Text] [Related]
16. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.
Leshem B; Kedar E
J Exp Med; 1990 Apr; 171(4):1057-71. PubMed ID: 2139097
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
Toffaletti DL; Darrow TL; Scott DW
J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
[TBL] [Abstract][Full Text] [Related]
19. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
20. Immune responses against allogeneic and syngeneic tumors in aged C57BL/6 mice.
Win S; Uenaka A; Nakayama E
Microbiol Immunol; 2002; 46(7):513-9. PubMed ID: 12222940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
